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Abstract. Background: Clofarabine is a second-generation
nucleoside analogue. The aim of the study was the analysis
of ex vivo activity of clofarabine and 14 other anticancer
drugs in pediatric and adult acute lymphoblastic (ALL) and
myeloid (AML) leukemia. Patients and Methods: The ex
vivo drug resistance profile was analyzed in 282 patients,
including 201 children with ALL de novo, 24 children with
relapsed ALL, 25 children with AML de novo and 32 adults
with AML. Cellular ex vivo drug resistance was tested by
means of the MTT assay. Results: Clofarabine had
comparable ex vivo activity against lymphoblasts and
myeloblasts, both on initial diagnosis and at relapse, both
in children and in adults. Its activity in acute myeloid
leukemia was independent of patient age. No significant
differences in drug resistance to clofarabine between
pediatric age-based subgroups of ALL were detected, while
it was observed for most of other drugs. An activity of
clofarabine in relapsed pediatric ALL patients was as good
as in newly-diagnosed ones. Conclusion: In comparison to
childhood acute lymphoblastic leukemia, lack of differences
in ex vivo activity gives rationale for use of clofarabine in
refractory and relapsed pediatric and adult patients with
acute myeloid leukemia.
The treatment of pediatric acute leukemias has improved
considerably in recent decades, with complete response rates
approaching approximately 90%  in some subgroups.
However, about 20-25%  children with ALL and 40-50%
with AML still relapse (1-3). The results in adults with acute
leukemia are worse, and hematopoietic stem cell
transplantation (HSCT) has not improved the outcome
significantly (4-6). Treatment of relapse after HSCT is still
very poor (7). The discovery and development of
clofarabine, a second-generation nucleoside analogue,
provides an important chance for relapsed patients (8). This
drug received accelerated approval from the US FDA at the
end of 2004 for the treatment of pediatric patients 1-21 years
old with relapsed or refractory acute lymphoblastic leukemia
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after at least two prior regimens. It is the first such drug to be
approved for pediatric leukemia in more than a decade, and
the first to receive approval for pediatric use before adult use
(9, 10). Clofarabine has demonstrated significant activity in
children (11-15) and adults (16-18) with refractory
lymphoid and myeloid leukemia in early clinical trials.
Originally developed to capture the best qualities of
cladribine and fludarabine, clofarabine contains halogenated
carbons, rendering it resistant to inactivating enzymes and
maintaining its stability in acidic environments. Like other
adenosine nucleosides, clofarabine acts by inhibiting
ribonucleotide reductase and DNA polymerase, thereby
depleting the amount of intracellular deoxynucleoside
triphosphates available for DNA replication, resulting in
premature DNA chain termination and inhibition of DNA
repair. Clofarabine has also been shown to induce apoptosis
in transformed cell lines, indicating that this drug results in
cell death in both cycling and non-cycling cells (19).
The aim of the study was the analysis of in vitro activity
of clofarabine and 14 other anticancer drugs in pediatric and
adult acute leukemia. 
Patients and Methods
Patients and leukemic cells. A total of 282 patients were tested for
the ex vivo drug resistance profile. The group included 201 children
with ALL de novo (median age 6 years, range 1-18 years), 24
children with relapsed ALL (median age 9 years, range 4-18 years),
25 children with AML de novo (median age 13 years, range 1-18
years) and 32 adults with AML (both de novo and relapsed)
(median age 39 years, range 18-52 years). Adult AML patients were
partially included in a previous report (20), while it was not the case
for children. Since ex vivo drug resistance in adult AML de novo
and at relapse are comparable (20, 21), all adult AML patients were
pooled together in one group for further analysis. Patients aged <1
year or with ALL with L3 (FAB) morphology were not included
into the study.
Samples of bone marrow (BM) were collected in a heparinised
tube (or 15-20 U heparine was used for 1 mL BM). Before
testing, the samples were diluted 1:1 or more with RPMI-1640
(Sigma, St Louis, MO, USA). In case of the presence of small
clots, the sample of BM was first filtered through a cell strainer
(70 μm nylonfilter; Falcon, Franklin Lakes, New Jersey, USA)
using RPMI-1640 to rinse off the strainer. Leukemic cells were
separated on Ficoll gradient at 540g for 20 minutes at room
temperature. After centrifugation, cells were washed twice with
RPMI-1640. The viability and recovery of the cells was tested by
trypan blue exclusion assay. Cell morphology and percentage of
blasts was analysed on cytospine slides stained with May-
Grunwald-Giemsa (MGG) method. Only samples with at least
90%  lymphoblasts and 70%  myeloblasts, both in the beginning
and at the end of the assay, were included into the study. The
study was approved by local Ethics Committee and informed
consent was obtained from all patients. 
Cells. Cells were maintained in RPMI 1640 medium, supplemented
with 2 mM glutamine and 20%  FBS. Culture medium was
supplemented with 100 U/mL penicillin (Polfa Tarchomin, Poland),
100 μg/mL streptomycin (Polfa Tarchomin, Poland), 200 μg/mL
gentamycin (Krka, Slovenia) and 0.125 μg/mL amphotericine B.
The culture was carried out in conditions of 5%  CO2, 37˚C and
95%  humidity. 
Drugs. The following 15 drugs were used: prednisolone (Jelfa,
Jelenia Gora, Poland; concentrations tested: 0.0076-250 μg/mL),
vincristine (Gedeon Richter, Budapest, Hungary; 0.019-20
μg/mL), L-asparaginase (Medac, Hamburg, Germany; 0.0032-10
IU/mL), daunorubicin (Rhone-Poulenc Rorer, France; 0.0019-2
μg/mL), doxorubicin (Pharmacia Italia S.p.A., Milan, Italy; 0.031-
40 μg/mL), cytarabine (Upjohn, Puurs, Belgium; 0.24-250
μg/mL), cladribine (Bioton, Warsaw, Poland; 0.0004-40 μg/mL),
etoposide (Bristol-Myers Squibb, Sermoneta, Italy; 0.048-50
μg/mL), 4-HOO-cyclophosphamide (Asta Medica, Hamburg,
Germany; 0.096-100 μg/mL), 4-HOO-ifosfamide (Asta Medica;
0.096-100 μg/mL), fludarabine phosphate (Schering AG, Berlin,
Germany; 0.019-20 μg/mL), idarubicin (Pharmacia; 0.0019-2
μg/mL), mitoxantrone (Jelfa; 0.001-1 μg/mL), 6-thioguanine
(Sigma; nr A4882, 1.56-50 μg/mL) and clofarabine (Evoltra,
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Table I. Drug resistance in pediatric and adult AML.
Drug Pediatric AML Adult AML RR p-value
(n=25) (n=32)
Prednisolone 226.96 (n=15) 181.45 (n=20) 0.8 0.259
13.92->250 21.48->250
Vincristine 3.71 (n=14) 5.315 (n=21) 1.4 0.575
0.41->20 0.63-11.89
Idarubicin 0.155 (n=21) 0.13 (n=24) 0.8 0.256
0.06->2 0.02->2
Daunorubicin 0.31 (n=14) 0.285 (n=21) 0.9 0.098
0.09->2 0.01->2
Doxorubicin 0.975 (n=8) 1.1 (n=18) 1.1 0.911
0.4->8 0.39->8
Mitoxantrone 0.1285 (n=23) 0.0709 (n=22) 0.6 0.603
0.0086->1 0.021->1
Etoposide 5.15 (n=14) 8.748 (n=21) 1.7 0.145
1.45->50 0.86->50
L-asparaginase 1.19 (n=14) 1.47 (n=20) 1.2 0.324
0.04->10 0.04->10
6-Thioguanine 4.23 (n=8) 8.85 (n=16) 2.1 0.176
1.56->50 2.52->50
4-HOO-cyclopho- 1.88 (n=8) 2.8 (n=19) 1.5 0.119
sphamide 0.35-2.27 0.17-4.63
4-HOO-ifosfamide 13.505 (n=4) 16.395 (n=16) 1.2 0.704
10.62-16.39 2.91-33.82
Cytarabine 0.27 (n=23) 1.15 (n=25) 4.3 0.198
0.03->10 0.05->10
Fludarabine 0.3125 (n=23) 0.9509 (n=24) 3.0 0.536
0.1477->20 0.0984->20
Cladribine 0.404 (n=23) 1.237 (n=24) 3.1 0.753
0.0022->40 0.0006->40
Clofarabine 0.055 (n=17) 0.06 (n=24) 1.1 0.954
0.01->12.5 0.01->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM,
and all other drugs in μg/mL. Drug resistance is given as median and
range of IC50; n – number of patients, RR – relative resistance.
Bioenvision, Edinburgh, UK; 0.0122-12.5 μM). Before the assay
was done, most drug stock solutions were stored frozen in small
aliquots at –20˚C, except cladribine, which was stored at +4˚C.
Stock solutions were prepared in water for injection, further
dilution was made in respective medium.
The MTT assay. Cellular drug resistance was tested by means of
the MTT assay. The procedure of the assay has been described
previously (22). The concentration of drug that was inhibitory to
50%  of the cells (IC50) was calculated from the dose-response
curve and was used as a measure for ex vivo drug resistance in
each sample. Relative resistance (RR) between analyzed groups
for each drug was calculated as a ratio of median value of IC50
for this drug. 
Statistical analysis. The Mann-Whitney U-test and Kruskal-Wallis
test were performed to compare differences in drug sensitivity
between analyzed groups. All tests were 2-sided with p-value of
0.05 being considered as significant.
Results
In comparison to childhood AML, no significant differences
were reported in the ex vivo drug resistance in adult AML
(Table I). There were also no differences in cellular drug
resistance between de novo and relapsed adult AML.
Activity of clofarabine was comparable in pediatric and
adult AML samples (Figure 1). No difference in drug ex
vivo activity against myeloblasts were observed between age
groups of AML patients, both in children (Tables II and III)
and in adults.
Pediatric AML was more ex vivo resistant to most drugs,
reaching statistical difference for prednisolone, vincristine,
L-asparaginase, daunorubicin, idarubicin and etoposide
(Table IV). Activity of clofarabine in ALL and AML de novo
in pediatric samples was comparable.
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Table II. Drug resistance in children with acute myeloid leukemia with
respect to age.
Drug <10 years >10 years RR p-value
(n=10) (n=15)
Prednisolone 214.57 (n=6) 238.5 (n=9) 1.1 0.589
31.25->250 13.92->250
Vincristine 4.17 (n=6) 2.845 (n=8) 0.7 0.118
3.1->20 0.41-6.84
Idarubicin 0.095 (n=9) 0.195 (n=12) 2.1 0.271
0.08->2 0.06->2
Daunorubicin 0.23 (n=6) 0.416 (n=8) 1.8 0.105
0.09->2 0.28->2
Doxorubicin 0.73 (n=6) 1.52 (n=2) 2.1 0.495
0.42->8 1.52-1.52
Mitoxantrone 0.0905 (n=8) 0.144 (n=15) 1.6 0.783
0.037->1 0.009-1
Etoposide 4.23 (n=6) 6.125 (n=8) 1.4 0.566
1.61->50 1.45->50
L-asparaginase 0.84 (n=6) 1.325 (n=8) 1.6 0.431
0.04->10 0.07->10
6-Thioguanine 2.65 (n=6) 5.81 (n=2) 2.2 0.495
1.56->50 5.81-5.81
4-HOO-Cyclo- 2.385 (n=4) 1.805 (n=4) 0.8 0.218
phosphamide 0.35->100 1.34-2.27
4-HOO-Ifosfamide 10.62 (n=2) 16.39 (n=2) 1.5 0.183
10.62->100 16.39-16.39
Cytarabine 0.135 (n=8) 0.44 (n=15) 3.3 0.269
0.03->10 0.04->10
Fludarabine 0.1914 (n=9) 0.525 (n=14) 2.7 0.131
0.148->20 0.159->20
Cladribine 0.2265 (n=8) 0.54 (n=15) 2.4 0.251
0.003->40 0.002->40
Clofarabine 0.042 (n=8) 0.056 (n=9) 1.3 0.226
0.01->12.5 0.03->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM,
and all other drugs in μg/mL. Drug resistance is given as median and
range of IC50; n – number of patients, RR – relative resistance.
Figure 1. Comparative values of median cytotoxicity of clofarabine with respect to diagnosis and age. cALL – childhood ALL de novo, rALL –
relapsed ALL, cAML – childhood AML de novo, aAML – adult AML; age groups: 1-5, 5-10, 10-15, 15-18 years.
With respect to age groups in ALL, it was found that
emerging ex vivo drug resistance occurs with age for
prednisolone, vincristine and L-asparaginase (Table V). For
all other drugs, this trend was also observed. Activity of
clofarabine against lymphoblasts was comparable in all age
groups. Activity of cytarabine was highest in patients with
age 1-5, while for all other age groups, it was comparable.
Activity of fludarabine and cladribine was decreased in
patients aged over 10. 
Relapsed ALL samples were more ex vivo resistant to all
tested drugs in comparison to de novo ALL samples for
prednisolone, vincristine, L-asparaginase and daunorubicin
(Table VI). Activity of clofarabine in newly-diagnosed and
relapsed lymphoblasts was similar (Figure 1). There were no
significant differences in relapsed blasts to cytarabine,
fludarabine and cladribine, when compared to ALL de novo
samples. 
Discussion
The development of drug resistance is the limiting factor in
the therapy of ALL and AML, both in children and in
adults. Although a proportion of the acute leukemias
occurring predominantly in children are presently curable
by chemotherapy, relapse still remains the main problem.
In adults, more than 50%  AML patients are at risk of
therapy failure. In spite of continuous improvement in
hematopoietic stem cell transplantation procedures and
targeted therapy, there is a need to search for the new drugs
in conventional chemotherapy. A second-generation
nucleoside analogue, clofarabine, might be a valuable
chemotherapeutic option due to its activity in various
subtypes of acute leukemia. 
Cellular drug resistance in AML cells seems to be similar
throughout all age groups, however greater age has a worse
ANTICANCER RESEARCH 29: 1643-1650 (2009)
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Table III. Drug resistance in children over 10 years and adults with AML.
Drug 10-18 years Adults RR p-value
(n=15) (n=32)
Prednisolone 238.5 (n=9) 181.45 (n=20) 0.8 0.765
13.92->250 21.48->250
Vincristine 2.845 (n=8) 5.315 (n=21) 1.9 0.154
0.41-6.84 0.63-11.89
Idarubicin 0.195 (n=12) 0.13 (n=24) 0.7 0.138
0.06->2 0.02->2
Daunorubicin 0.416 (n=8) 0.285 (n=21) 0.7 0.308
0.28->2 0.01->2
Doxorubicin 1.52 (n=2) 1.1 (n=18) 0.7 0.206
1.52-1.52 0.39->8
Mitoxantrone 0.144 (n=15) 0.0709 (n=22) 0.5 0.433
0.009-1 0.021->1
Etoposide 6.125 (n=8) 8.748 (n=21) 1.4 0.149
1.45->50 0.86->50
L-Asparaginase 1.325 (n=8) 1.47 (n=20) 1.1 0.124
0.07->10 0.04->10
6-Thioguanine 5.81 (n=2) 8.85 (n=16) 1.5 0.259
5.81-5.81 2.52->50
4-HOO-Cyclo- 1.805 (n=4) 2.8 (n=19) 1.6 0.495
phosphamide 1.34-2.27 0.17-4.63
4-HOO-Ifosfamide 16.39 (n=2) 16.395 (n=16) 1.0 1.000
16.39-16.39 2.91-33.82
Cytarabine 0.44 (n=15) 1.15 (n=25) 2.6 0.463
0.04->10 0.05->10
Fludarabine 0.525 (n=14) 0.9509 (n=24) 1.8 0.855
0.159->20 0.0984->20
Cladribine 0.54 (n=15) 1.237 (n=24) 2.3 0.320
0.002->40 0.0006->40
Clofarabine 0.056 (n=9) 0.06 (n=24) 1.1 0.125
0.03->12.5 0.01->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM,
and all other drugs in μg/mL. Drug resistance is given as median and
range of IC50; n – number of patients, RR – relative resistance.
Table IV. Drug resistance in pediatric ALL and AML de novo samples.
Drug ALL de novo AML de novo RR p-value
(n=201) (n=25)
Prednisolone 27.59 (n=159) 226.96 (n=15) 8.2 0.021
0.01->250 13.92->250
Vincristine 0.35 (n=158) 3.71 (n=14) 10.6 0.006
0.01953->20 0.41->20
Idarubicin 0.06 (n=114) 0.155 (n=21) 2.6 0.016
0.01->2 0.06->2
Daunorubicin 0.18 (n=157) 0.31 (n=14) 1.7 0.051
0.01->2 0.09->2
Doxorubicin 0.81 (n=90) 0.975 (n=8) 1.2 0.958
0.1->8 0.4->8
Mitoxantrone 0.043 (n=112) 0.1285 (n=23) 3.0 0.287
0.0034->1 0.0086->1
Etoposide 1.2 (n=154) 5.15 (n=14) 4.3 0.006
0.048->50 1.45->50
L-asparaginase 0.19 (n=159) 1.19 (n=14) 6.3 0.018
0.032->10 0.04->10
6-Thioguanine 3.25 (n=84) 4.23 (n=8) 1.3 0.739
1.5625-50 1.56->50
4-HOO-Cyclo- 0.8 (n=83) 1.88 (n=8) 2.4 0.335
phosphamide 0.19->100 0.35-2.27
4-HOO-Ifosfamide 8.28 (n=42) 13.505 (n=4) 1.6 0.349
0.33->100 10.62-16.39
Cytarabine 0.85 (n=158) 0.27 (n=23) 0.3 0.152
0.05->10 0.03->10
Fludarabine 0.525 (n=114) 0.3125 (n=23) 0.6 0.399
0.01953-20 0.1477->20
Cladribine 0.075 (n=112) 0.404 (n=23) 5.4 0.104
0.0025-40 0.0022->40
Clofarabine 0.04 (n=128) 0.055 (n=17) 1.4 0.916
0.01->12.5 0.01->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM,
and all other drugs in μg/mL. Drug resistance is given as median and
range of IC50; n – number of patients, RR – relative resistance.
clinical outcome. Previous and current studies suggest that
adult AML is not more in vitro resistant than childhood
AML (reviewed in (21)). In childhood AML, no drug is
more effective in comparison to ALL, and cellular drug
resistance is partially related to chromosomal abnormalities
(23, 24). Pediatric AML is equally resistant as adult AML.
Pediatric and adult AML are possibly equally drug resistant
on initial diagnosis and at relapse (21, 25). Thus, the
difference in outcome between childhood and adult AML
cannot be explained by clinically significant differences in
an in vitro drug resistance measured with the MTT assay
and therefore might reflect other differences such as
pharmacokinetics. Another explanation may be that a small
subpopulation of resistant cells cannot be detected using the
MTT assay.
Contrary to children, adults with AML in 20-50%  cases are
primarily resistant to induction chemotherapy, and clinical
resistance to the first cycle of induction chemotherapy is an
independent prognostic factor. The resistance to chemotherapy
is represented by a characteristic gene-expression profile
which distinguishes AML patients with good or poor
responses. Genes highly expressed in poor responders are also
overexpressed in hematopoietic stem/progenitor cells. In
multivariate analysis, the treatment-response signature was an
independent prognostic factor. Resistance to chemotherapy in
AML can be identified by gene-expression profiling before
treatment and seems to be mediated by a transcriptional
program active in hematopoietic stem/progenitor cells (26).
Microarray technology should lead to the identification of
additional gene targets linked to the treatment response of
specific cytogenetic leukemia subgroups.
Cellular drug resistance is one of the main causes of the
frequent ultimate failure of chemotherapy in childhood AML.
It appears that cellular drug resistance differs between AML
and ALL. Taking into account both children and adults, age is
adversely related to therapy outcome in AML, and the
percentage of patients with favorable cytogenetics decreases
with age; however age is positively correlated with multi-drug
Styczynski et al: Comparison of Clofarabine Activity
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Table V. Drug activity in pediatric ALL with respect to age groups.
Drug 1-5 years (n=71) 5-10 years (n=63) 10-15 years (n=26) 15-18 years (n=31) p-value
Prednisolone 25.49 (n=58) 28.4 (n=53) 61.24 (n=21) 148.03 (n=27) 0.031
0.08->250 0.28->250 0.01->250 0.19->250
Vincristine 0.345 (n=57) 0.36 (n=52) 1.88 (n=21) 2.19 (n=28) 0.004
0.03-9.8 0.02-9.33 0.0195->20 0.08->20
Idarubicin 0.075 (n=38) 0.05 (n=39) 0.09 (n=14) 0.08 (n=23) 0.035
0.02->2 0.02-0.63 0.01->2 0.06->2
Daunorubicin 0.215 (n=58) 0.135 (n=52) 0.27 (n=19) 0.22 (n=28) 0.252
0.02->2 0.04->2 0.01->2 0.05->2
Doxorubicin 0.825 (n=26) 0.77 (n=31) 1.03 (n=11) 1.13 (n=22) 0.093
0.1->8 0.23->8 0.4->8 0.43->8
Mitoxantrone 0.0504 (n=38) 0.0345 (n=38) 0.0592 (n=14) 0.0501 (n=22) 0.559
0.0084->1 0.003->1 0.0053->1 0.0092->1
Etoposide 1.38 (n=56) 0.81 (n=52) 2.93 (n=18) 2.06 (n=28) 0.265
0.032->50 0.048->50 0.06->50 0.11->50
L-Asparaginase 0.075 (n=59) 0.395 (n=52) 0.71 (n=20) 3.65 (n=28) 0.001
0.04->10 0.04->10 0.05->10 0.07->10
6-Thioguanine 3.79 (n=26) 2.07 (n=27) 6.82 (n=9) 5.285 (n=22) 0.064
1.5625->50 1.563->50 1.5625->50 3.13-18.37
4-HOO-Cyclophosphamide 0.985 (n=25) 0.865 (n=32) 0.8 (n=10) 0.64 (n=16) 0.873
0.28->100 0.26->100 0.19-23.4 0.45-6.25
4-HOO-Ifosfamide 6.91 (n=15) 13.845 (n=16) 10.335 (n=6) 5.25 (n=5) 0.461
0.33->100 12.5-15.19 1.56-49.12 4.79-19.43
Cytarabine 0.595 (n=38) 1.49 (n=39) 2.28 (n=14) 1.3 (n=23) 0.029
0.07->10 0.06->10 0.05->10 0.23->10
Fludarabine 0.31815 (n=37) 0.625 (n=40) 1.0511 (n=15) 0.7875 (n=22) 0.111
0.0881->20 0.02->20 0.0886->20 0.1477->20
Cladribine 0.0988 (n=38) 0.0244 (n=38) 0.4 (n=14) 5.0357 (n=22) 0.020
0.0117-12.65 0.003->40 0.0068->40 0.0132->40
Clofarabine 0.04 (n=44) 0.04 (n=43) 0.055 (n=15) 0.068 (n=26) 0.372
0.01-8.61 0.01->12.5 0.01->12.5 0.01->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM, and all other drugs in μg/mL. Drug resistance is given as median and range
of IC50; n - number of patients. p-value was calculated by Kruskal-Wallis test.
resistance and the proportion of patients with unfavorable
cytogenetics. Increased incidence of unfavorable cytogenetics
contributes to the poor outcome in AML. Within each
cytogenetic risk group, treatment outcome deteriorates
markedly with age. The distinct biology and clinical
responses seen argue for age-specific assessments when
evaluating therapies for AML.
Pediatric AML is more resistant than pediatric ALL
(23, 27, 28). When ex vivo drug resistance profile in
childhood ALL and AML were compared, almost no drug
was found to be more effective in AML in comparison to
ALL. Childhood acute lymphoblastic and myeloid
leukemia have different cellular drug resistance profiles.
Using the MTT assay, it has been shown that AML cells
were significantly more resistant than ALL cells to
glucocorticoids, vincristine, L-asparaginase,
anthracyclines, mitoxantrone, etoposide and ifosfamide;
while the sensitivity was equal for cytarabine. These
findings were reported previously (23). On the other hand,
clofarabine was as active in AML as in ALL.
In the comparative study of adults with ALL, AML and B-
lineage CLL (chronic lymphocytic leukemia), B-CLL cells
were found to be more sensitive than cells from both AML
and ALL to cytarabine, cladribine, fludarabine, doxorubicin,
idarubicin, vincristine and cyclophosphamide (29). No
difference in cellular drug resistance was found between B-
CLL and ALL cells for prednisolone, whereas AML cells
were more resistant. However, B-CLL cells acquired cellular
drug resistance during therapy, as cells obtained from
patients who had received previous chemotherapy were more
resistant to almost all tested drugs as compared to cells from
treatment-naive patients (29).
In the study of Beesley et al. (30) on pediatric ALL cell
lines, clofarabine was marginally more active in B-lineage
than T-lineage ALL. The differences in clofarabine ex vivo
activity between precursor-B-lineage and T-lineage ALL was
not observed in the presented pediatric cohort, and this might
contribute to general profile of good clofarabine activity
against lymphoblasts. 
Pediatric relapsed ALL is regarded as highly drug resistant
diseases, both in ex vivo individual tumor response testing
and in clinical practice (31, 32). No differences in ex vivo
activity of clofarabine between de novo and relapsed ALL
patients were observed, while high resistance to
prednisolone, vincristine, daunorubicin and L-asparaginase
was found on relapse. Adult ALL samples were not tested in
this study. Adult ALL is a more drug resistant disease than
childhood ALL at first diagnosis (33, 34). There are some
discrepancies in results comparing cellular drug resistance in
adult ALL between initial diagnosis and relapse (28, 29), yet
there are probably no differences between these two groups
of patients (29).
In conclusion, it has been shown that clofarabine has
comparable activity against lymphoblasts and myeloblasts,
both on initial diagnosis and at relapse, and both in
children and in adults, which suggests the potential for use
of clofarabine in refractory and relapsed patients with
acute leukemia. Although a trend was observed for
increasing resistance to clofarabine in adolescents with
ALL, the difference was smaller than for most of drugs,
which are currently in use of therapy of childhood ALL.
On the other hand, a large variability of IC50 values was
observed in all tested groups, thus considerable overlap
occurred between all patients. Differences in drug
resistance to clofarabine between pediatric age-based
subgroups of ALL were not detected. 
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Table VI. Drug activity in de novo and relapsed childhood ALL.
Drug ALL de novo ALL relapsed RR p-value
(n=201) (n=24)
Prednisolone 27.59 (n=159) 137.39 (n=21) 5.0 0.002
0.01->250 31.25->250
Vincristine 0.35 (n=158) 2.26 (n=22) 6.5 0.037
0.01953->20 0.12->20
Idarubicin 0.06 (n=114) 0.13 (n=14) 2.2 0.110
0.01->2 0.03->2
Daunorubicin 0.18 (n=157) 0.875 (n=21) 4.9 0.024
0.01->2 0.07->2
Doxorubicin 0.81 (n=90) 1.92 (n=13) 2.4 0.240
0.1->8 0.09->8
Mitoxantrone 0.043 (n=112) 0.0602 (n=14) 1.4 0.471
0.0034->1 0.0025->1
Etoposide 1.2 (n=154) 2.65 (n=18) 2.2 0.170
0.048->50 0.13->50
L-Asparaginase 0.19 (n=159) 0.72 (n=22) 3.8 0.015
0.032->10 0.06->10
6-Thioguanine 3.25 (n=84) 5.86 (n=11) 1.8 0.133
1.5625-50 2.37->50
4-HOO-Cyclo- 0.8 (n=83) 2.1 (n=10) 2.6 0.175
phosphamide 0.19->100 0.11->100
4-HOO-Ifosfamide 8.28 (n=42) 18.985 (n=8) 2.3 0.144
0.33->100 4.69->100
Cytarabine 0.85 (n=158) 1.63 (n=14) 1.9 0.175
0.05->10 0.04->10
Fludarabine 0.525 (n=114) 0.711 (n=14) 1.4 0.304
0.01953-20 0.1226->20
Cladribine 0.075 (n=112) 0.1719 (n=14) 2.3 0.840
0.0025-40 0.0016->40
Clofarabine 0.04 (n=128) 0.043 (n=17) 1.1 0.908
0.01->12.5 0.01->12.5
Concentration of L-asparaginase is given in IU/mL, clofarabine in μM,
and all other drugs in μg/mL. Drug resistance is given as median and
range of IC50; n – number of patients, RR – relative resistance.
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